Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 1

Status

Terminated 1Recruiting 1Completed 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 4Gastrointestinal 4Tumor-Agnostic 3Head & Neck 2Gynecologic 2CNS 2Thoracic 1Sarcoma 1Plasma cell 1Lymphoid 1Dermatologic 1Breast 1

Conditions

Neoplasms 3Neoplasm Metastasis 1

Interventions

Gemcitabine 26Paclitaxel 24pembrolizumab 23Carboplatin 22Bevacizumab 18Radiotherapy 16Oxaliplatin 16Erlotinib Hydrochloride 16Nivolumab 15Cisplatin 14Capecitabine 14Fluorouracil 13Trastuzumab 12Docetaxel 12atezolizumab 11Magnetic Resonance Spectroscopy 11Leucovorin 11Cyclophosphamide 11Irinotecan 10Ipilimumab 10Vemurafenib 9Everolimus 9Cetuximab 9cabozantinib 8Radiosurgery 8Afatinib 8130-nm albumin-bound paclitaxel 8trametinib 7lenvatinib 7durvalumab 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Vaccines × Tumor-Agnostic × Clear all
NCT04948619 2026-01-22

Immune Function and Response to Vaccination After Cancer Therapy in Pediatric Patients

Wake Forest University Health Sciences

Phase 2 Recruiting
64 enrolled
Tumor-Agnostic

Neoplasms

NCT06175221 2025-09-15

Autologous TLPO Vaccine Basket

Elios Therapeutics, LLC

Phase 2 Terminated
63 enrolled
Tumor-Agnostic

Neoplasm Metastasis, Neoplasms

NCT00505063 2025-06-15

Prospective Trial of Vaccine Responses in Childhood Cancer Survivors

Memorial Sloan Kettering Cancer Center

Phase 2 Completed
76 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡